Podcast

Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates

Author(s):

Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these differences, and ways these disparities can be addressed.

Welcome to OncLive On Air®! I’m your host today, Chris Ryan.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with David Goldberg, MD, an associate professor of medicine in the Division of Digestive Health and Liver Diseases at the Miller School of Medicine at the University of Miami, and Daniel Sussman, MD, an associate professor of clinical medicine at the Miller School of Medicine and a researcher at the Sylvester Comprehensive Cancer Center, to discuss research on above-average rates of mortality from gastric cancer in South Florida.

Faculty from Sylvester Comprehensive Cancer Center collaborated with gastroenterologists, epidemiologists, and oncologists to study gastrointestinal deaths by county in the United States to identify factors associated with differences in mortality and potential ways to reduce disparities in different areas.

The research demonstrated that the counties with the highest 5% of mortality rates for gastric, pancreatic, and colorectal cancer were primarily in the Southeastern portion of the United States. Researchers pointed to smoking and living in rural areas as the factors most closely linked with gastrointestinal cancer–related mortality.

Regarding the high rates of mortality for gastric cancer in South Florida, a higher prevalence of a bacteria called Helicobacter pylori (H. pylori), which is more common in parts of the world such as South America, could contribute to the disparities in outcomes seen in the area.

In our exclusive interview, Drs Goldberg and Sussman discussed the key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these differences, and ways these disparities can be addressed.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

Related Videos
Janaki Neela Sharma, MD
Justin M. Watts, MD
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Janaki Neela Sharma, MD, University of Miami
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Janaki Neela Sharma, MD